Global Lewy Body Dementia Market Pipeline 2016 Review Report

PUNE, India, May 16, 2016 /PRNewswire/ --

ReportsnReports.com adds "Lewy Body Dementia - Pipeline Review, H1 2016" market research report covering comprehensive information on the therapeutic development for Lewy body Dementia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lewy body Dementia and special features on late-stage and discontinued projects.

Complete report on H1 2016 pipeline review of Lewy body Dementia with 17 market data tables and 11 figures, spread across 40 pages is available at http://www.reportsnreports.com/reports/541479-lewy-body-dementia-pipeline-review-h1-2016.html .

The report also reviews key players involved in the therapeutic development for Lewy body Dementia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies discussed in this Lewy body Dementia Pipeline Review, H1 2016 report include Axovant Sciences Ltd., BioArctic Neuroscience AB, Immungenetics AG and Sumitomo Dainippon Pharma Co., Ltd. Drug profiles discussed in this research report includes BAN-0805, nelotanserin, RVT-101, Small Molecule to Activate ABC Transporter for Neurodegeneration Disorders, Small Molecules to Agonize M1 Muscarinic Acetylcholine Receptor for Lewy Body Dementia and Parkinson''s Disease Dementia and zonisamide.

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Lewy body Dementia and reviews pipeline therapeutics for Lewy body Dementia by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Lewy body Dementia therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Lewy body Dementia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Lewy body Dementia.

Order a copy of Lewy body Dementia - Pipeline Review, H1 2016 market research report @ http://www.reportsnreports.com/Purchase.aspx?name=541479 .

List of Tables 

Number of Products under Development for Lewy body Dementia, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Lewy body Dementia - Pipeline by Axovant Sciences Ltd., H1 2016

Lewy body Dementia - Pipeline by BioArctic Neuroscience AB, H1 2016

Lewy body Dementia - Pipeline by Immungenetics AG, H1 2016

Lewy body Dementia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Lewy body Dementia Therapeutics - Recent Pipeline Updates, H1 2016

Lewy body Dementia - Dormant Projects, H1 2016

Another newly published market research report titled on Alzheimer's Disease - Pipeline Review, H1 2016 provides comprehensive information on the therapeutic development for Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alzheimer's Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Alzheimer's Disease Pipeline market research report of 1249 pages is available at http://www.reportsnreports.com/reports/525203-alzheimers-disease-pipeline-review-h1-2016.html .

Explore more reports on Pharmaceuticals.

About Us:   

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
sales@reportsandreports.com

Connect With Us on:
Facebook:https://www.facebook.com/ReportsnReports/
LinkedIn:https://www.linkedin.com/company/reportsnreports
Twitter:  https://twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
RSS/Feeds:  http://www.reportsnreports.com/feed/l-latestreports.xml